Anticancer agent 48

Cat. No.: HY-146357: FAQs
Data Sheet Handling Instructions

Molarity Calculator

Anticancer agent 48 (compound 48) is a broad spectrum anticancer agent. Anticancer agent 48 inhibits tubulin polymerization. Anticancer agent 48 shows antiproliferative activity. Anticancer agent 48 shows antitumor activity in vivo. Anticancer agent 48 has the potential for the research of solid and hematological tumors.

For research use only. We do not sell to patients.

Anticancer agent 48 Chemical Structure

CAS No. : 2395009-13-7

Size		Stock
MOQ		Minimum order quantity
50 mg		Get quote
100 mg		Get quote
250 mg		Get quote
Other size		Get quote

Synthetic products have potential research and development risk.

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description

Cellular Effect

Cell Line	Type	Value	Description	References
HCT-116	IC₅₀	27 nM Compound: 48	Cytotoxicity against human HCT116 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 31727471]
HT-29	IC₅₀	51 nM Compound: 48	Cytotoxicity against human HT-29 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human HT-29 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 31727471]
KBM5	IC₅₀	14 nM Compound: 48	Cytotoxicity against human KBM5 cells expressing IM- sensitive wild type Bcr/Abl assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human KBM5 cells expressing IM- sensitive wild type Bcr/Abl assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 31727471]
KBM5	IC₅₀	16 nM Compound: 48	Cytotoxicity against human KBM5 cells expressing IM-resistant Bcr/Abl T315I mutant assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human KBM5 cells expressing IM-resistant Bcr/Abl T315I mutant assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 31727471]
KU812 cell line	IC₅₀	8 nM Compound: 48	Cytotoxicity against human KU812 cells expressing IM- sensitive wild type Bcr/Abl assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human KU812 cells expressing IM- sensitive wild type Bcr/Abl assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 31727471]
MCF7	IC₅₀	14 nM Compound: 48	Cytotoxicity against human MCF7 cells assessed as reduction in cell growth incubated for 96 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell growth incubated for 96 hrs by MTT assay	[PMID: 31727471]
MCF7	IC₅₀	14 nM Compound: 1	Cytotoxicity against human MCF7 cells assessed as cell growth inhibition measured after 96 hrs Cytotoxicity against human MCF7 cells assessed as cell growth inhibition measured after 96 hrs	[PMID: 34052717]
SW480	IC₅₀	48 nM Compound: 48	Cytotoxicity against human SW480 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human SW480 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 31727471]
SW-620	IC₅₀	28 nM Compound: 48	Cytotoxicity against human SW620 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human SW620 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 31727471]
T-24	IC₅₀	12 nM Compound: 48	Cytotoxicity against human T24 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human T24 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 31727471]
T98G	IC₅₀	36.6 nM Compound: 48	Cytotoxicity against human T98G cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay Cytotoxicity against human T98G cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay	[PMID: 31727471]
U-87MG ATCC	IC₅₀	30.9 nM Compound: 48	Cytotoxicity against human U87MG cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay Cytotoxicity against human U87MG cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay	[PMID: 31727471]

In Vitro

Anticancer agent 48 (compound 48) inhibits tubulin polymerization and MCF-7 cancer cell growth with IC₅₀s of 0.47 µM and 14 nM, respectively^[1].
Anticancer agent 48 shows antiproliferative activity with IC₅₀s of 8, 10, 12, 14, 16 nM for KU812, LAMA84-S, LAMA84-R, KBM5-WT, KBM5-T315I cells, respectively^[1].
Anticancer agent 48 shows growth inhibition with IC₅₀s of 12, 31, 37, 221, 56, 27, 51, 48, 28, 12 nM for U343G, U87MG, T98G, SK-N-BE, SK-N-BE(2)-C, HT29, HCT116, SW480, SW620, T24 cell, respectively^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Anticancer agent 48 (20 mg/kg; i.p.; every 2 days for 40 days) shows antitumor effects^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	8 week-old female BALB/C^nu/nu mice (EZ-2 or T24 cells)^[1]
Dosage:	20 mg/kg
Administration:	I.p.; every 2 days for 40 days
Result:	Significantly inhibited cancer cell proliferation, in vivo tumorigenesis, and tumor angiogenesis.

Molecular Weight

443.49

Formula

C₂₆H₂₅N₃O₄

CAS No.

2395009-13-7

SMILES

COC1=CC(C(C2=CN(C=C2C3=CC=C(C=C3)N)C4=CC=CC(N)=C4)=O)=CC(OC)=C1OC

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Handling Instructions (2659 KB)

References

[1]. Puxeddu M, et al. Structure-activity relationship studies and in vitro and in vivo anticancer activity of novel 3-aroyl-1,4-diarylpyrroles against solid tumors and hematological malignancies. Eur J Med Chem. 2020 Jan 1;185:111828. [Content Brief]